The Nutritional Status of Chemo-radiotherapy Patients (PANSOCRP)

July 15, 2020 updated by: Charles Darwin University

Prospective Analysis of the Nutritional Status of Chemo-radiotherapy Patients

Cancer patients are one of the patient groups at highest risk for the development of malnutrition. Anti-cancer treatments, such as chemotherapy and radiotherapy, can further heighten the risk due to the nutrition-related toxicities experienced during this time.

This study aims to baseline the nutritional status of chemo-radiotherapy patients undergoing treatment at the Alan Walker Cancer Care Centre (Darwin), identify contributors to nutritional deterioration and determine if there is a difference between Indigenous and non-Indigenous patients.

Study Overview

Status

Completed

Conditions

Detailed Description

Background: Cancer patients are at a greater risk of malnutrition. Limited data exists on the development of malnutrition during chemo - radiotherapy, particularly in rural and remote areas of Australia. Additionally, there is no data on the nutritional status of cancer patients in the Northern Territory or areas with a high proportion of Indigenous Australians. While considering the aforementioned dearth of literature, we are conducting a study in Darwin, Northern Territory of Australia. This study aims to establish a baseline of the nutritional status of chemo - radiotherapy patients undergoing treatment at the Alan Walker Cancer Care Centre (Darwin), to identify contributing factors to nutritional deterioration, and to determine if there is a difference between Indigenous and non-Indigenous patients. This study will provide a prospective analysis of malnutrition and a clear insight of nutritional status of cancer patients. It presents the first of its kind to address the nutritional status of cancer patients in Indigenous Australians.

Methods/ design: Using the Patient Generated-Subjective Global Assessment; all eligible patients will be assessed for malnutrition and consented for participation into this study. Each participant's nutritional status will be assessed at baseline, first week of treatment, final week of treatment, and at one month post treatment. Prevalence data will be analysed using percentages. Comparative data will be analysed using chi-square tests. A linear regression analysis of the results will be undertaken. Data will be analysed using SPSS version 20 (IBM SPSS).

Discussion: Weight loss and malnutrition among cancer patient is well documented, however, results from our study might appear to be more remarkable when compared with the other published data, because of our participants demographic, assessment tool used: the Patient Generated-Subjective Global Assessment has not been validated for use in Indigenous Australian Keywords: Nutritional status, malnutrition, prospective analysis, chemo-radiotherapy

Study Type

Observational

Enrollment (Actual)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Northern Territory
      • Darwin, Northern Territory, Australia, 0810
        • Alan Walker Cancer Care Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adults (18 years or over) who are being treated with curative intent chemo-radiotherapy at the Alan Walker Cancer Care Centre during the data collection period

Description

Inclusion Criteria:

  • 18 years or over undergoing curative intent chemo-radiotherapy at AWCCC
  • Able to speak basic English or have an interpreter present
  • Able to provide consent

Exclusion Criteria:

  • Pregnant or breast feeding women
  • Non-English speaking background where interpreter not available
  • Change to single modality treatment (ie change from chemo-radiotherapy to chemotherapy or radiotherapy alone) or change to treatment intent (ie change from curative intent to palliative intent)
  • Violent or aggressive patients to maintain the safety of investigators

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The prevalence of malnutrition amongst chemo-radiotherapy patients
Time Frame: 1 year
1 year

Secondary Outcome Measures

Outcome Measure
Time Frame
The incidence of the development of malnutrition during chemo-radiotherapy
Time Frame: 1 year
1 year

Other Outcome Measures

Outcome Measure
Time Frame
Factors contributing to the development of malnutrition
Time Frame: 1 year
1 year
The difference between Indigenous and non-Indigenous in respect to their nutritional status
Time Frame: 1 year
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Loise Moodie, Royal Darwin Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2013

Primary Completion (Actual)

December 1, 2014

Study Completion (Actual)

December 1, 2015

Study Registration Dates

First Submitted

August 29, 2013

First Submitted That Met QC Criteria

September 4, 2013

First Posted (Estimate)

September 9, 2013

Study Record Updates

Last Update Posted (Actual)

July 16, 2020

Last Update Submitted That Met QC Criteria

July 15, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HREC2013 1973

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Subscribe